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Abstract: Amoebiasis caused by Entamoeba histolytica is associated with high morbidity 
and mortality is becoming a major public health problem worldwide, especially in 
developing countries. Because of the side-effects and the resistance that pathogenic protozoa 
build against the standard antiparasitic drugs, e.g., metronidazole, much recent attention has 
been paid to plants used in traditional medicine around the world in order to find new 
antiprotozoal agents. We collected 32 plants used in Northeast Mexican traditional 
medicine and the methanolic extracts of these species were screened for antiprotozoal 
activity against E. histolytica trophozoites using in vitro tests. Only 18 extracts showed a 
significant inhibiting activity and among them six plant extracts showed more than 80% 
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growth inhibition against E. histolytica at a concentration of 150 µg/mL and the IC50 values 
of these extracts were determined. Lippia graveolens Kunth and Ruta chalepensis Pers. 
showed the more significant antiprotozoal activity (91.54% and 90.50% growth inhibition 
at a concentration of 150 µg/mL with IC50 values of 59.14 and 60.07 µg/mL, respectively). 
Bioassay-guided fractionation of the methanolic extracts from these two plants  
afforded carvacrol (1) and chalepensin (2), respectively, as bioactive compounds with 
antiprotozoal activity. 
Keywords: neglected diseases; amoebiasis; Mexican medicinal plants; bioguided isolation; 
carvacrol; chalepensin; antiprotozoal agents; 1D- and 2D-NMR data 
 
1. Introduction 
An estimated billion people are infected with one or more neglected tropical diseases [1–4]. 
Amoebiasis caused by Entamoeba histolytica, a protozoan of the family Endomoebidae [5,6], is 
associated with high morbidity and mortality and has become a major public health problem 
worldwide [7] and is therefore considered as the third parasitosis of medical importance after malaria 
and schistosomiasis [8]. E. histolytica is still endemic in tropical and sub-tropical regions, causing a 
high incidence of infections in developing countries in Latin America, Asia and Africa [9], where poor 
sanitary conditions, population explosion and inadequate control of reservoirs intensify the development 
of these infections [10]. The amoebiasis is prevalent throughout the developing nations with tropical 
ecosystems, at times reaching a prevalence of 50% of the general population and is estimated to cause 
more than 100,000 deaths per year [11,12]. Symptomatic patients typically may develop abdominal 
pain and tenderness, diarrhea, and bloody stools, but the disease may spread to the liver and other 
organs resulting in death [13,14]. 
Currently metronidazole is the therapeutic drug of choice for the treatment of amoebiasis [15], but 
is experiencing drug resistance by E. histolytica [16,17], resulting in the need for increased doses to 
overcome the infection [18] and thus causing unpleasant side-effects, such as headache, nausea, dry 
mouth, and a metallic taste, as well as neurotoxicity [19,20]. Owing to these undesired side effects and 
taking into account the development of resistant strains of E. histolytica against metronidazole, new, 
more effective and safer antiprotozoal agents are urgently required [20,21]. Natural products have 
proved to be an important source of lead compounds in the development of new drugs and artemisinin, 
quinine and licochalcone A are all examples of plant-derived products with antiparasitic activity [22,23]. 
Screening natural products provides the chance to discover new molecules of unique structure with 
high activity and selectivity [24]. 
Thus, with the purpose of searching for new antiprotozoal agents, 32 medicinal plants used in 
Northeast Mexican traditional medicine [25,26] were selected to evaluate the activity of their methanol 
crude extracts against E. histolytica trophozoites. The selection of the species was mainly based on a 
follow up of ethnobotanical uses for the treatment or relief of symptoms related with parasitic infections. 
  
Molecules 2014, 19 21046 
 
 
2. Results and Discussion 
2.1. In Vitro Susceptibility Assays of Plant Extracts 
In this work, we report the antiprotozoal activity of 32 crude methanolic extracts derived from plants 
used in Northeast Mexico for the treatment of gastrointestinal disorders. The yields after Soxhlet extraction 
of each plant are shown in Table 1. 
Table 1. Soxhlet extraction of medicinal plants used in Northeast Mexico investigated for 
antiprotozoal activity. 
Scientific Name Family  
Voucher 
Specimen
Part Used a 
Yield  
(%w/w) b
Agave lechugilla Torr Agavaceae 025529 L 16.5 
Amphipterygium adstringens Standley Julianaceae 025530 B 18.8 
Apium graveolens Linnaeus Apiaceae 025531 S 5.7 
Arctostaphylos pungens Kunth Ericaceae 025532 FR 23.3 
Artemisia mexicana Willd Asteraceae 025533 L 15.3 
Bougainvillea spectabilis Willd Nyctaginaceae 025535 F 24.5 
Capsicum annuum Linnaeus Solanaceae 025536 FR 37.9 
Castela texana Torr & Grey Simaroubaceae 025538 L 14.0 
Cecropia obtusifolia Bertol Cecropiaceae 025539 AP 12.6 
Coriandrum sativum Linnaeus Apiaceae 025540 L 31.8 
Cyclolepis genistoides Don Asteraceae 025541 L 16.5 
Cymbopogon citrates Stapf Poaceae 025542 L 17.6 
Eryngium heterophyllum Engelm Apiaceae 025544 A 15.3 
Eucalyptus globulus Labill Myrtaceae 025545 L 10.8 
Foeniculum vulgare Miller P. Apiaceae 025546 L 12.4 
Gnaphalium oxyphyllum DC Asteraceae 025572 L 11.2 
Gymnosperma glutinosum Spreng Asteraceae 025547 AP 39.9 
Haematoxylon brasiletto Karsten Leguminosae 025548 L 18.8 
Heterotheca inuloides Cass Asteraceae 025549 AP 16.3 
Hibiscus sabdariffa Linnaeus Malvaceae 025550 F 44.0 
Juglans mollis Engelm Juglandaceae 025551 L 6.3 
Lippia graveolens Kunth Verbenaceae 025554 AP 41.0 
Marrubium vulgare Linnaeus Lamiaceae 025555 AP 15.6 
Melissa officinalis Linnaeus Lamiaceae 025557 L 17.9 
Mentha spicata Crantz Lamiaceae 025558 L 18.9 
Ocimum basilicum Linnaeus Lamiaceae 025559 L 18.5 
Opuntia ficus-indica Linnaeus Cactaceae 025560 CL 17.0 
Persea Americana Mill Lauraceae 025563 L 21.2 
Ruta chalepensis Pers Rutaceae 025579 AP 12.7 
Schinus molle Linnaeus Anacardiaceae 025567 AP 15.9 
Syzygium aromaticum Linnaeus Myrtaceae 025569 F c 39.9 
Tilia platyphyllos Scopoli Tiliaceae 025570 F 11.8 
a Plant part extracted: AP, aerial parts; B, barks; CL, cladodes; F, flowers; FR, fruits; L, leaves; S, seeds;  
b Percentage based on dried plant material; c Not opened flower. 
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In vitro susceptibility assays were performed for each crude extract. Table 2 summarizes the 
antiprotozoal activity on Entamoeba histolytica of the plant extracts and the control drug (metronidazole). 
Extracts from 18 out of the 32 samples tested showed significant growth inhibition of E. histolytica 
with percentage values ranging from 24.65 to 91.54 at a concentration of 150 µg/mL. The remaining 
12 plants showed absolutely no activity. Lippia graveolens Kunth, Ruta chalepensis Pers,  
Capsicum annuum Linnaeus, Opuntia ficus-indica Linnaeus, Haematoxylon brasiletto Karsten and 
Schinus molle Linnaeus displayed more than 80% growth inhibition against E. histolytica at a 
concentration of 150 µg/mL, with IC50 values ranging from 32.45 to 98.75 µg/mL, far less effective 
than metronidazole (IC50 0.205 µg/mL), but these IC50 values are suitable as selection criterion for 
further investigation of these plant extracts as source of potential antiprotozoal agents [10]. 
Table 2. Antiprotozoal activity against Entamoeba histolytica of methanolic extracts a 
from selected plants. 
Plant Specimen % Growth Inhibition b IC50 of Crude Extract (µg/mL) b 
Lippia graveolens Kunth 91.54 59.14 
Ruta chalepensis Pers 90.50 60.07 
Capsicum annuum Linnaeus 87.87 98.75 
Opuntia ficus-indica Linnaeus 87.47 70.33 
Haematoxylon brasiletto Karsten 84.84 96.38 
Schinus molle Linnaeus 81.79 32.45 
Melissa officinalis Linnaeus 76.95 c 
Castela texana Torr & Grey 73.82 c 
Cyclolepis genistoides Don 73.80 c 
Juglans mollis Engelm 71.87 c 
Agave lechugilla Torr 69.66 c 
Mentha spicata Crantz 65.72 c 
Tilia platyphyllos Scopoli 65.00 c 
Gymnosperma glutinosum Spreng 63.80 c 
Gnaphalium oxyphyllum DC 42.15  c 
Apium graveolens Linnaeus 29.03 c 
Cecropia obtusifolia Bertol 29.00 c 
Persea americana Mill 24.65 c 
a Adjusted to a concentration of 150 µg/mL; b Metronidazole 100% growth inhibition (IC50 = 0.205 µg/mL);  
c IC50 was not determined. 
It is important to point out that the antiprotozoal activity of seven plants chosen for this work has been 
previously reported. However, we decided to evaluate these species again because the antiprotozoal 
activity was tested with different parasites or extracts. From Lippia graveolens the biological activity 
mainly of its essential oils against Giardia lamblia [27–29] and Leishmania infantum [30] has been 
reported. There have been previous reports describing the activity of methanolic extracts (macerated at 
room temperature) of Artemisia mexicana, Ocimum basilicum, Ruta chalepensis and Schinus molle 
against trophozoites of E. histolytica and G. lamblia [10], reporting IC50 values for these plants of 
82.2, 41.7, 61.9 and 82.4 µg/mL, respectively, against E. histolytica. Although we observed a similar 
IC50 to the one reported by Calzada [10] for R. chalepensis, we did not notice any activity for  
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A. mexicana and O. basilicum, but observed higher activity for S. molle, which could be explained by 
the fact that the plant material was provided by different regional suppliers. In addition, R. chalepensis 
also showed activity against L. infantum and L. major [31], and S. molle also showed activity against 
Plasmodium falciparum, Trypanosoma brucei, T. cruzi, and L. infantum [32]. Melissa officinalis has 
demonstrated biological activity reported against cysts and trophozoites of Acanthamoeba castellanii [33]. 
Some reports on Castela texana revealed that the ethanolic extract of aerial parts and the methanolic 
extract from roots have relevant amebicide activity [34–36]. We also found good amebicide activity 
for this plant (73.82% growth inhibition at a concentration of 150 µg/mL) by using leaves for the 
preparation of a methanolic extract. 
To our knowledge, this is the first report of antiprotozoal activity against Entamoeba histolytica  
of extracts from Agave lechugilla Torr, Apium graveolens Linnaeus, Capsicum annuum Linnaeus, 
Cecropia obtusifolia Bertol, Cyclolepis genistoides Don, Gnaphalium oxyphyllum DC,  
Gymnosperma glutinosum Spreng, Haematoxylon brasiletto Karsten, Juglans mollis Engelm,  
Melissa officinalis Linnaeus, Mentha spicata Crantz, Opuntia ficus-indica Linnaeus, Persea americana 
Mill and Tilia platyphyllos Scopoli. 
2.2. Phytochemistry of Bioactive Plants against Entamoeba histolytica 
There are few reports relating to the antiprotozoal activity of pure compounds isolated from the plants 
included in this study. Some flavonoids occurring in L. graveolens, e.g., apigenin, (−)-epigallocatechin, 
galangin, kaempferol, narigenin, pinocembrin and quercetin [37,38] showed biological activity against 
E. histolytica and G. lamblia [39]. Chaparrin (a simaroubolidane), presenting 100% growth inhibition 
against E. histolytica at a concentration of 100 µg/mL, was isolated from the roots of Castela texana [34]. 
The isolated quassinoid from C. texana, 11-O-trans-p-coumaroyl amarolide also presented antimalarial 
activity [40]. 
For the other bioactive plants no reports concerning antiprotozoal activity were found, but 
remarkable phytochemical research has been done in order to isolate the bioactive compounds 
responsible for different biological activities. Phytochemical studies showed the presence of steroidal 
saponins with anti-inflammatory properties in Agave lechugilla [41–43]. From Apium graveolens  
β-selinene and sedanolide with mosquitocidal, nematicidal and antifungal activity have been  
isolated [44,45]. Furthermore, sesquiterpenoid, phtalide, aromatic and lignan glucosides were isolated 
from A. graveolens [46,47]. Several capsaicinoids with antioxidant activity [48] as well as 
sesquiterpenoids with cytotoxic activity [49] have been isolated from Capsicum annuum. In addition, 
various phenylpropanoids with inhibitory action against Listeria monocytogenes were isolated from  
C. annuum [50]. A phytochemical study of Andrade-Cetto et al. [51] confirmed the hypoglycemic 
effect of chlorogenic acid and isoorientin, main components of Cecropia obtusifolia. Several triterpenes 
and sesquiterpene lactones have been isolated from Cyclolepis genistoides [52]. Moreover, oleanolic 
acid and deacylcynaropicrin, compounds with anti-inflammatory properties, were isolated from  
C. genistoides [53]. From Gnaphalium oxyphyllum several diterpenoids, acetylenic compounds,  
and carotenoids with antimicrobial activity have been isolated [54]. It has been reported that 
Gymnosperma glutinosum contains flavonoids and diterpenes with antimicrobial, antifungal and cytotoxic 
activities [25,55,56]. From Haematoxylon brasiletto the neoflavonoids hematoxylin and brazilin as well 
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as caffeic acid, gallic acid and 4-hydroxycinammic acid, all of them compounds with antimicrobial 
activity, have been isolated [57]. Several monoterpene hydrocarbons, caffeate oligomers, flavonoids 
and terpenoids have been identified in Melissa officinalis [58,59]. Many terpenes isolated from the 
essential oils of Mentha spicata possess a wide spectrum of biological activity against many pathogenic 
bacteria, fungi and some protozoa [60]. From Opuntia ficus-indica the alkaloids indicaxanthin and 
neobetanin as well as various flavonoids have been isolated [61]. (E,Z,Z)-1-Acetoxy-2-hydroxy-4-oxo-
heneicosa-5,12,15-triene was isolated from avocado, Persea americana; it inhibited spore germination of 
the fungal pathogen Colletotrichum gloeosporioides [62]. Furthermore, persenone A and B with good 
activity as inhibitors of nitric oxide and superoxide generation were isolated from Persea Americana [63]. 
Several furanocoumarins and quinoline alkaloids with antimicrobial [64] and larvicidal [65] activities 
have been isolated from Ruta chalepensis. Likewise several sesquiterpenoids, triterpenoids and flavonoids 
have been isolated from Schinus molle [66]. From Tilia platyphyllos some monoterpenic hydrocarbons 
and alcohols as well as flavonoids have been identified [67–69]. 
Neither chemical nor biological reports concerning antiprotozoal activity of Juglans mollis could be 
found in the literature, but from the related plant Juglans regia oleic, linoleic, α-linoleic and ellagic 
acid as well as the flavonoid juglamin have been isolated [70,71]. 
Bioassay-guided fractionation of the bioactive extracts from the plants included in this study will be 
carried out in order to isolate pure compounds related to their antiprotozoal activity. Lippia graveolens 
Kunth and Ruta chalepensis Pers showed the most significant antiprotozoal activity (91.50 and 90.50% 
growth inhibition at a concentration of 150 µg/mL with IC50 values of 59.14 and 60.07 µg/mL, 
respectively), therefore these plants were the first choice for subsequent work on the isolation of their 
active constituents. 
2.3. Isolation and Structure Elucidation of Compounds with Antiprotozoal Activity 
Bioassay-guided fractionation of the methanolic extract from L. graveolens rendered carvacrol (1) 
with 95%–98% inhibition against E. histolytica at a concentration of 150 µg/mL (IC50 44.3 µg/mL) 
and from the methanolic extract of R. chalepensis chalepensin (2) with 98.4% inhibition at a 
concentration of 150 µg/mL (IC50 45.95 µg/mL) was recovered. Identification of the isolated 
compounds was based on spectroscopic/spectrometric analyses (IR, 1H- and 13C-NMR; MS) and 
comparison with literature data. The corresponding chemical structures are shown in Figure 1. 
Figure 1. Structure of carvacrol (1) and chalepensin (2). 
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2.3.1. Carvacrol from Lippia graveolens 
Preliminary fractionation of the methanolic extract of Lippia graveolens by extraction with n-hexane 
led, after evaporation of solvent, to a residue with good activity against E. histolytica (90.9% growth 
inhibition at a concentration of 150 µg/mL). Chromatography of this hexane residue over a silica gel 
column led to the isolation of carvacrol (1) as a colorless oil. Spectroscopic data of 1 were in 
concordance with literature values [72–74]. 
The essential oil of Lippia graveolens contains many monoterpenes, sesquiterpenes and phenolic 
terpenes among which carvacrol and thymol are the most common components [75–77] and their 
average abundance establishes the chemotype that can be assigned to L. graveolens varieties [78–80]. 
Due to its acidic and hydrophobic nature, carvacrol tends to damage biological systems and for that 
reason is responsible for affecting a wide range of microorganisms, including bacteria, fungi, yeast and 
parasites [81–85]. It also has been proposed as a therapeutic agent against some cancer cell lines due to 
its activity as an antiproliferative compound [86,87], DNA synthesis inhibitor [88] and by triggering 
apoptosis [89,90]. 
The monoterpenic phenol exerts a bactericidal effect against many foodborne bacteria responsible 
for gastrointestinal disorders, such as Listeria monocytogenes, Escherichia coli [91], Salmonella enterica 
ser. Enteritidis [92], Bacillus subtillis, Salmonella typhimurium, Escherichia coli [93,94], Shigella sonnei, 
S. flexeri [95] and it has been considered useful to inhibit the growth of microorganisms responsible for 
respiratory disorders like Staphyloccocus aureus, Staphyloccocus aureus MSRA, Streptococcus pneumonie, 
Klebsiella pneumonie, Pseudomonas auroginosa [85]. Carvacrol is also able to inhibit the enterotoxin 
production from Bacillus cereus, which generates abdominal pain and diarrhea [96]. 
Important toxigenic and pathogenic filamentous fungi, some causative of serious human mycoses, 
have been subjected to carvacrol exposure and antifungal properties were found for this compound 
against Aspergillus niger, A. flavus, A. fumigatus, Penicillum digitatum, P. brevicompactum,  
P. expansum and Fusarium spp. [97–99]. Carvacrol has also shown strong fungicidal effects against 
many clinical isolates from Candida spp. and Cryptococcus spp. [97,100]. 
Furthermore, carvacrol was tested against many tropical parasites responsible for serious human 
diseases. Thus, the compound was evaluated for its trypanocidal activity against Trypanosoma cruzi and 
T. brucei rhodesiense, being very effective in both cases, with IC50 values under 30 µg/mL [101–103], 
but noteworthily an important inhibition effect was observed on the epimastigote form in T. cruzi 
isolates (IC50 3.0 µg/mL). Following this topic, carvacrol was evaluated against visceral parasites of 
the genus Leishmania and the results demonstrated an important effectiveness range over the 
promastigote form of Leishmania chagasi with IC50 values between 2.3 to 28 µg/mL [103,104]. A 
weak activity was observed on Leishmania donovani with an IC50 value of 17.8 mg/mL, compared 
with the reference drug miltefosine (IC50 0.14 mg/mL). In addition, antimalarial activity against 
Plasmodium falciparum was tested, obtaining a very significant IC50 value of 7.9 mg/mL [85]. 
Prior to our investigation, amebicide evaluation of carvacrol had not been carried out on  
E. histolytica, but one clinical study was performed on 14 adult patients, whose stools tested positive 
for enteric parasites such as Entamoeba hartmanni, Endolimax nana and Blastocystis hominis. The 
patients were supplemented with an essential oil rich in carvacrol from Origanum vulgare and after  
6 weeks of treatment total disappearance of E. hartmanni and E. nana was observed in all infected 
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patient cases. B. hominis was not detected in five cases [105]. Nevertheless this is the first report about 
the antiprotozoal activity of carvacrol against Entamoeba histolytica. 
2.3.2. Chalepensin from Ruta chalepensis 
The bioguided fractionation of the methanolic extract of Ruta chalepensis by partition between 
methanol and n-hexane followed by chromatography of the hexane residue (84.66% growth inhibition 
against E. histolytica at a concentration of 150 µg/mL) over a silica gel column afforded chalepensin 
(2) as colorless needles with a melting point of 75 °C. The spectroscopic data were identical with those 
reported for chalepensin [106–113], but we now report the complete, unambiguous assignment of the 
13C-NMR spectrum of chalepensin as the hydrogen and carbon connectivities in 2 were deduced from 
1H-1H COSY, NOESY, HSQC and HMBC spectra. 
Chalepensin has been isolated from several herbs, especially those of the Rutaceae family, including 
Ruta chalepensis [114–120]. Chalepensin has strong allelochemical and phytotoxic activity [121–123]. 
Moreover, chalepensin has a variety of pharmacological effects, including a significant anti-fertility 
activity [124], antiplatelet aggregation activity [112], cytotoxic effects on some human carcinoma cell lines 
(breast MCF-7; colon HT-29; kidney A-498; lung A-549; pancreatic PACA-2; prostate PC-3) [122], 
and further antiproliferative activity against human gastric adenocarcinoma (MK-1), human uterus 
carcinoma (HeLa) and murine melanoma (B16F10) cells [125]. It has been also proved that 
chalepensin is a mechanism-based inhibitor of cytochrome P450 (CYS) 2A6 [126–128]. This is the 
first report on the antiprotozoal activity against Entamoeba histolytica of chalepensin. 
2.4. Possible Antiprotozoal Mechanism of Action of Carvacrol and Chalepensin 
Little knowledge exists about the antiprotozoal mechanism of action of carvacrol but the 
antimicrobial mechanisms of action of carvacrol have been thoroughly investigated [81–85]. In the 
following, we describe some facts of these antimicrobial mechanisms which future research might 
reveal if these apply as well to protozoa. Carvacrol exhibits antimicrobial activity against the 
biological membranes of bacteria. It exerts its action by rapidly depleting the intracellular ATP pool by 
reducing ATP synthesis and increasing ATP hydrolysis. Reduction of transmembrane electric potential 
which is the driving force of ATP synthesis enhances proton permeability of the membrane. At 1 mM 
carvacrol lowers the internal pH of bacteria from 7.1 to 5.8 according to ion gradients of the cell 
membrane. Carvacrol (1 mM) decreases cell protein content from 12 mmol/mg to 0.99 mmol/mg by 
using potassium (K+) of bacterial cells in a short time (5 min). Potassium (K+) plays a role in the 
activation of cytoplasmic enzymes, in maintaining osmotic pressure and in the regulation of 
cytoplasmic pH. Leakage of K+ out of the cell is a clear indication of membrane damage. Ultee et al. [82] 
hypothesized a scheme for the mechanism of action of carvacrol through the cytoplasmic membrane of 
bacteria. According to this hypothesis undissociated carvacrol diffuses through the cytoplasmic 
membrane and dissociates releasing its proton to the cytoplasm. It then returns undissociated through 
the membrane into the external environment carrying a potassium ion. Outside the cell carvacrol 
replaces potassium with a proton and reenters the cell the same way. 
The mechanism of action of oregano oils has been shown to be related, especially, to the synthesis 
of structural components and to the disruption of a series of energy systems. The leakage of ions, ATP 
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and amino acids from bacterial cells explains this phenomenon. Potassium and phosphate ion 
concentrations were affected at a rate much lower than their MIC values [85]. 
Carvacrol increases overall permeability of the cytoplasmic membrane by disrupting the outer 
membranes of Gram negative bacteria leading to the leakage of ATP from the cell. Carvacrol also 
inhibits ATPase [85]. Similar alterations to those observed in bacteria [85] were also observed on 
Giardia lamblia exposed to essential oils from different sources, especially those where carvacrol had a 
dominant presence (over 70% of general composition) [28]. The main ultrastructural alterations 
promoted by essential oils were deformations in typical trophozoite appearance, often roundly shaped, 
irregular dorsal and ventral surface, presence of membrane blebs, electrodense precipitates in the 
cytoplasm and nuclei and internalization of flagella and ventral disc. The data suggest that essential oils 
probably induced cell death by processes associated to the loss of osmoregulation caused by plasmatic 
membrane alterations [28]. 
To our knowledge there are no studies regarding the antiprotozoal mechanism of chalepensin but 
chalepin, a furocoumarin structural related to chalepensin, exerts a potent inhibitory activity against the 
recombinant enzyme TcGAPDH (glyceraldehyde-3-phosphate dehydrogenase) of Trypanosoma cruzi with 
a strong IC50 of 64 µM [129,130]. Further studies are required to establish the antiprotozoal 
mechanism of carvacrol and chalepensin against E. histolytica. 
3. Experimental Section 
3.1. General 
Melting points were determined on an Electrothermal 9100 apparatus (Electrothermal Engineering Ltd., 
Southend on Sea, UK). IR spectra were recorded on a Frontier FT-IR spectrometer (PerkinElmer, 
Waltham, MA, USA) using an ATR accessory. NMR spectra were measured on a Avance DPX 400 
Spectrometer (Bruker, Billerica, MA, USA) operating at 400.13 MHz for 1H and 100.61 MHz for 13C. 
ESI HR mass spectra were measured on a 4.7 T FT-ICR Mass spectrometer (Bruker, Bremen, 
Germany). EI MS was recorded on a MAT 95 spectrometer (70 eV, Finnigan, San Jose, CA, USA). 
TLC was carried out on pre-coated silica gel glass plates 5 cm × 10 cm (Merck silica gel 60 F254, 
Darmstadt, Germany). Normal phase column chromatography was performed on silica gel (60–200 mesh) 
purchased from J. T. Baker (Phillipsburg, NJ, USA). 
3.2. Plant Material 
The plants were obtained from the field or purchased from Pacalli® (pacalli.com.mx, Monterrey, 
Mexico). Reference vouchers of the plant material were deposited at the herbarium UNL of the 
Facultad de Ciencias Biológicas (Universidad Autónoma de Nuevo León). Plant species, botanical 
name, family, voucher specimens and plant parts used to obtain the extracts are summarized in Table 1. 
Vegetal material was dried and ground to powder. 
3.3. Extraction and Isolation 
Sixty grams of dried and powdered material from the respective plant was extracted with methanol 
(MeOH, 600 mL) by using a Soxhlet system for continuous extraction. After filtration, the solvent was 
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evaporated under reduced pressure in a rotary evaporator [25]. The different extracts were conserved in 
tightly sealed glass vials. The yields are shown in Table 1. 
3.3.1. Bioguided Isolation of Carvacrol (1) 
Ground and dried leaves of Lippia graveolens (600 g) were extracted with methanol in several 
portions of 30 g in a Soxhlet apparatus for 40 h, each charged with 500 mL of CH3OH. After filtration 
of the methanol solutions, the solvent was removed under reduced pressure to yield 260 g of combined 
extract. The crude extract was analyzed for amebicide activity on trophozoites of E. histolytica 
(HM1:IMSS strain), showing a very high inhibition percentage (89%) by standard concentration of 
150 µg/mL. Afterwards, the extract was redissolved in 2 L methanol, being divided in 4 portions of 
500 mL each and submitted to liquid-liquid partition with n-hexane (500 mL each portion) to yield, 
after solvent evaporation, 19.9 g of a combined residue with high amebicidal activity (90.9% growth 
inhibition). The n-hexane partition was divided into eighteen portions of ca. 1 g and each of them 
chromatographed on a silica gel (20 g) column (39 cm × 2 cm) and eluted with stepwise gradients of  
n-hexane–chloroform (100:0, 90:10, 80:20, 70:30, 60:40, 50:50, 40:60, 30:70, 20:80, 10:90, 0:100 v/v, 
each 50 mL), chloroform–ethyl acetate (90:10, 80:20, 70:30, 60:40, 50:50, 40:60, 30:70, 20:80, 10:90, 
0:100 v/v, each 50 mL), and finally with 50 mL methanol. A total of 110 subfractions (10 mL) were 
collected for each column and combined on the basis of their TLC (CHCl3–EtOAc, 9:1) profiles into 
six main fractions as follows: A (subfractions 1–30, 1.1 g), B (subfractions 31–42, 780 mg), C 
(subfractions 43–63, 7.1 g), D (subfractions 64–72, 2.5 g), E (subfractions 73–75, 1.9 g) and F 
(subfractions 76–110, 3.6 g). These main fractions, containing the non-polar to the more polar 
compounds, were used for amebicide assays. Only fraction C showed amebicide activity (82.88% 
growth inhibition) and was divided into seven portions of ca. 1 g and each of them chromatographed 
on a silica gel (20 g) column (39 × 2 cm) and eluted with stepwise gradient solvent system consisting 
of n-hexane–chloroform (100:0, 90:10, 80:20, 70:30, 60:40, 50:50, 40:60, 30:70, 20:80, 10:90, 0:100 
v/v, each 50 mL), and finally with 50 mL methanol. A total of 60 subfractions (10 mL) were collected 
and combined on the basis of their TLC (n-hexane–CHCl3, 2:8) profiles into three main fractions as 
follows: G (subfractions 1–27, 1.0 g), H (subfractions 28–38, 4.2 g), I (subfractions 39–60, 677 mg). 
The amebicide activity was detected on fraction G (44.24% growth inhibition) and very noticeable on 
fraction H (94.63% growth inhibition); this last was submitted to additional fractionation. Fraction H 
was divided into four portions of ca. 1 g and each of them later chromatographed on a silica gel  
(20 g) column (39 cm × 2 cm) and eluted with stepwise gradient solvent system consisting of  
n-hexane–chloroform (100:0, 90:10, 80:20, 70:30, 60:40, 50:50, 40:60, 30:70, 20:80, 10:90, 0:100 v/v, 
each 50 mL), and finally with 50 mL methanol. A total of 120 subfractions (5 mL) were collected and 
combined on the basis of their TLC (n-hexane–CHCl3, 2:8) profiles into three main fractions as 
follows: J (subfractions 1–63, 514 mg), K (subfractions 64–90, 1.7 g) and L (subfractions 91–120, 1.0 g). 
Fraction J (98.4% growth inhibition; IC50 44.30 µg/mL) and Fraction K (95.13% growth inhibition; 
IC50 44.22 µg/mL) both provided an oil containing a compound with a very intense and characteristic 
hydrocarbon smell (carvacrol, 1). Fraction L did not present amebicidal activity. 
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Carvacrol (1). Red colored oil; Rf = 0.40 (n-hexane–CHCl3, 2:8); IR (liquid film) vmax (cm−1): 3392, 
3020, 2959, 2927, 2869, 1873, 1720, 1621, 1590, 1523, 1458, 1382, 1363, 1252, 1232, 1173, 863, 810; 
1H-NMR (400 MHz, CHCl3-d): δ (ppm) = 7.06 (1H, d, J = 7.5 Hz, H-3), 6.74 (1H, d, J = 7.5 Hz, H-4), 
6.68 (1H, s, H-6), 5.37 (1H, br s, OH), 2.84 (1H, sept, J = 6.9 Hz, H-7), 2.24 (3H, s, H-10) 1.24 (6H, d, 
J = 6.9 Hz; H-8, H-9); 13C-NMR (100 MHz, CHCl3-d): δ (ppm) = 153.65 (Cq, C-1), 148.45 (Cq, C-5), 
130.83 (CH, C-3), 120.87 (Cq, C-2), 118.76 (CH, C-4), 113.01 (CH, C-6), 33.7 (CH, C-7), 24.02 (2 CH3; 
C-8, C-9), 15.34 (CH3, C-10); ESI-MS (+)-mode: m/z = 323.2 [2M+Na]+, 623.4 [4M+Na]+; ESI-MS 
(−)-mode: m/z = 149.1 [M−H]−, 195.1 [M+HCOO]−; (calcd. for C10H14O: 150.21). 
3.3.2. Bioguided Isolation of Chalepensin (2) 
Ground and dried leaves of Ruta chalepensis (600 g) were extracted with methanol in several portions 
of 30 g in a Soxhlet apparatus for 40 h, each charge with 400 mL of CH3OH. After filtration of the 
methanol solutions, the solvent was removed under reduced pressure to yield 124.0 g of combined 
extract. This extract was analyzed for anti-amoebic activity, showing a 90.5% growth inhibition on 
trophozoites of E. histolytica (HM1:IMSS strain). Afterwards, the extract was redissolved in 1 L of 
methanol, being divided into four portions of 250 mL each and submitted to liquid-liquid partition with 
n-hexane (750 mL each portion) to yield, after solvent evaporation, 8.2 g of a combined residue with 
high amebicidal activity (84.66% growth inhibition). The n-hexane partition was divided into eight 
portions of 1 g and each of them chromatographed on a silica gel (22 g) column (30 cm × 2 cm) and 
eluted with stepwise gradients of n-hexane–chloroform (100:0, 90:10, 80:20, 70:30, 60:40, 50:50, 
40:60, 30:70, 20:80, 10:90, 0:100 v/v, each 50 mL), chloroform–ethyl acetate (90:10, 80:20, 70:30, 
60:40, 50:50, 40:60, 30:70, 20:80, 10:90, 0:100 v/v, each 50 mL) and finally with 50 mL methanol.  
A total of 110 subfractions (10 mL) were collected for each column and combined on the basis of their 
TLC (CHCl3–ethyl acetate, 9.5:0.5) profiles into eight main fractions as follows: A (subfractions 1–22, 
328 mg), B (subfractions 23–30, 1197 mg), C (subfractions 31–34, 209 mg), D (subfractions 35–43, 
1184 mg), E (subfractions 44–49, 701 mg), F (subfractions 50–55, 649 mg), G (subfractions 56–61, 
494 mg), H (subfractions 62–110, 1134 mg). These main fractions, containing the non-polar to the more 
polar compounds, were used for amebicide assays, resulting in 12.51% growth inhibition for A, 93% 
for B, 88.26% for C, 89.87% for D, 88.47% for E, 92.05% F, 91.69% for G and 91.06% for H. 
Fraction B, showing good activity against trophozoites of E. histolytica and mainly one compound in 
TLC with a Rf of 0.41 (n-hexane–CHCl3, 3:7) was therefore submitted to additional fractionation. 
Fraction B was chromatographed again on a silica gel (22 g) column (30 cm × 2 cm) using a stepwise 
gradient solvent system consisting of chloroform–ethyl acetate (100:0, 90:10, 80:20, 70:30 v/v, each  
50 mL), and finally with 50 mL methanol. A total of 50 subfractions (5 mL) were collected, combined 
on the basis of their TLC (n-hexane–CHCl3, 3:7) profiles into five main fractions as follows:  
I (subfractions 1–10, 15 mg), J (subfractions 11–14, 456 mg), K (subfractions 15–24, 466 mg),  
L (subfractions 25–35, 67 mg), M (subfractions 36–50, 42 mg). Only Fraction J contained the compound 
with Rf of 0.41 (n-hexane–CHCl3, 3:7) and was subjected to additional purification on silica gel (22 g) 
column (30 cm × 2 cm) using a stepwise gradients of chloroform–ethyl acetate (100:0, 90:10 v/v, each  
200 mL). A total of 80 subfractions (5 mL) were collected, combined on the basis of their TLC  
(n-hexane–CHCl3, 3:7) profiles into four main fractions as follows: N (subfractions 1–11, 17 mg),  
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O (subfractions 12–17, 243 mg), P (subfractions 18–44, 92 mg), Q (subfractions 45–80, 18 mg). 
Fraction O produced pure chalepensin (2), showing 98.4% growth inhibition against E. histolytica and 
an IC50 value of 45.95 µg/mL. Fraction P was subjected to additional purification on a silica gel (22 g) 
column (30 cm × 2 cm) using stepwise gradients of chloroform–ethyl acetate (100:0, 95:05, v/v, each 
150 mL) and finally 50 mL of methanol as eluent. A total of 70 subfractions (5 mL) were collected, 
combined on the basis of their TLC (n-hexane–CHCl3, 3:7) profiles into three main fractions as 
follows: R (subfractions 1–27, 37 mg), S (subfractions 28–47, 24 mg) and T (subfractions 48–70, 8 mg). 
Fraction R rendered additional pure chalepensin. 
Chalepensin (2). Colorless needles; M.p. 75 °C; Rf = 0.41 (n-hexane–CHCl3, 3:7); IR (powder) vmax 
(cm−1): 3016, 2968, 2932,1715, 1629, 1583, 1542, 1451, 1024, 751; 1H-NMR (400 MHz, CDCl3-d): δ 
(ppm) = 7.68 (1H, s, H-4), 7.67 (1H, d, J = 2.24 Hz, H-2’), 7.65 (1H, s, H-5), 7.43 (1H, s, H-8), 6.82 
(1H, dd, J = 2.24, 0.96 Hz, H-3’), 6.21 (1H, dd, J = 17.2, 11.0 Hz, H-12), 5.10 (1H, s, H-13a-cis), 5.07 
(1H, dd, J = 8.16, 0.97 Hz, H-13b-trans), 1.52 (6H, s, 14-CH3, 5-CH3); 13C-NMR (100 MHz, CDCl3-d): 
δ (ppm) = 159.94 (Cq, C-2), 155.84 (Cq, C-7), 151.28 (Cq, C-9), 146.59 (CH, C-2’), 145.45 (CH, C-12), 
138.34 (CH, C-4), 133.09 (Cq, C-3) 124.57 (Cq, C-6), 119.52 (CH, C-5), 115.91 (Cq, C-10), 112.33 
(CH2, C-13), 106.35 (CH, C-1'), 98.95 (CH, C-8), 40.51 (Cq, C-11), 26.15 (2 CH3, C-14, C-15); ESI-MS 
(+)-mode: m/z = 255.1 [M+H]+, 277.1 [M+Na]+, 531.2 [2M+Na]+; (+)-ESI HR MS: m/z = 255.1014 
[M+H]+ (calcd. For C16H15O3: 255.1016), 277.0835 [M+Na]+ (calcd. for C16H14NaO3: 277.0835). 
3.4. Antiprotozoal Assay 
3.4.1. Test Microorganisms 
Entamoeba histolytica strain HM-1:IMSS was obtained from the microorganism culture collection 
of the Centro de Investigación Biomédica del Noreste (CIBIN-IMSS) in Nuevo León, Mexico.  
The trophozoites were grown axenically and maintained in peptone, pancreas and liver extract plus 
bovine serum [131]. The trophozoites were employed at log phase of growth (2 × 104 cells/mL) by all 
the performed bioassays [132,133]. 
3.4.2. In Vitro Assay for Entamoeba histolytica 
The MeOH extract from each plant was dissolved in DMSO and adjusted to a concentration of  
150 µg/mL in a suspension of E. histolytica trophozoites at logarithmic phase in PEHPS medium 
containing 10% of bovine serum. Vials were incubated for 72 h, then chilled in iced water for 20 min 
and the number of dead trophozoites per milliliter was counted by using a hemocytometer. Each 
extract assay was performed by triplicate [132,133]. Each test included a positive control by using 
metronidazole and a negative control by using E. histolytica suspension in PEHPS medium with no 
extract added. The inhibition percentage was estimated as the number of dead cells compared with the 
untreated controls. 
The same procedure was performed with fractions or pure isolated compounds. 
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3.4.3. In Vitro IC50 Determination 
The MeOH extract from each plant was dissolved in DMSO and adjusted to 150, 75, 32.5 and  
16.25 µg/mL with a suspension of E. histolytica trophozoites at logarithmic phase in PEHPS medium 
containing 10% of bovine serum. Vials were incubated for 72 h, then chilled in iced water for 20 min 
and the number of dead trophozoites per milliliter was determined by using a hemocytometer.  
Each extract assay was performed by triplicate. The 50% inhibitory (IC50) concentration of each 
extract was determined by using a Probit analysis with a 95% confidence level. The same procedure 
was performed with fractions or pure isolated compounds. 
4. Conclusions 
Entamoeba histolytica is the most common parasite to cause enteric protozoan infections. The drug 
of choice used to treat amoebic dysentery is metronidazole, which has been associated with unpleasant 
side effects [134–136], therefore alternative drugs are needed and medicinal plants may be an 
important alternative source of new antiamoebic compounds. The results of the antiprotozoal screening 
in this work support the popular uses of 18 of the studied species for the treatment of diarrhea and 
dysentery in Mexican traditional medicine. The extracts from both Lippia graveolens Kunth and  
Ruta chalepensis Pers showed the most significant antiprotozoal activity and were submitted to a 
bioguided fractionation. Structure elucidation of the isolated compounds was accomplished by 
spectroscopic and mass spectrometric data. The methanolic extract of L. graveolens rendered carvacrol 
(1) with 95%–98% inhibition against E. histolytica at a concentration of 150 µg/mL (IC50 44.3 µg/mL) 
and from the methanolic extract of R. chalepensis chalepensin (2) with 98.4% inhibition at a 
concentration of 150 µg/mL (IC50 45.95 µg/mL) was recovered. To our knowledge, this is the first 
report on the antiamoebic activity of carvacrol and chalepensin, both known compounds with other 
notable pharmacological activities. These compounds may also offer new opportunities for treating 
amoebiasis and other important and often neglected diseases [137] or be useful as lead compounds in 
the development of new antiprotozoal agents. Further work for isolation of other active constituents 
from these plants is under way. 
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